Literature DB >> 26158910

Inhibition of Ebola virus glycoprotein-mediated cytotoxicity by targeting its transmembrane domain and cholesterol.

Moritz Hacke1, Patrik Björkholm2, Andrea Hellwig3, Patricia Himmels1, Carmen Ruiz de Almodóvar1, Britta Brügger1, Felix Wieland1, Andreas M Ernst1.   

Abstract

The high pathogenicity of the Ebola virus reflects multiple concurrent processes on infection. Among other important determinants, Ebola fusogenic glycoprotein (GP) has been associated with the detachment of infected cells and eventually leads to vascular leakage and haemorrhagic fever. Here we report that the membrane-anchored GP is sufficient to induce the detachment of adherent cells. The results show that the detachment induced through either full-length GP1,2 or the subunit GP2 depends on cholesterol and the structure of the transmembrane domain. These data reveal a novel molecular mechanism in which GP regulates Ebola virus assembly and suggest that cholesterol-reducing agents could be useful as therapeutics to counteract GP-mediated cell detachment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26158910     DOI: 10.1038/ncomms8688

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  66 in total

1.  Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.

Authors:  Z Y Yang; H J Duckers; N J Sullivan; A Sanchez; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  2000-08       Impact factor: 53.440

2.  Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

Authors:  W Weissenhorn; A Carfí; K H Lee; J J Skehel; D C Wiley
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

3.  Processing of the Ebola virus glycoprotein by the proprotein convertase furin.

Authors:  V E Volchkov; H Feldmann; V A Volchkova; H D Klenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  [On the etiology of an unknown human infection originating from monkeys].

Authors:  R Siegert; H L Shu; W Slenczka; D Peters; G Müller
Journal:  Dtsch Med Wochenschr       Date:  1967-12-22       Impact factor: 0.628

Review 5.  The multiple roles of sGP in Ebola pathogenesis.

Authors:  Marc-Antoine de La Vega; Gary Wong; Gary P Kobinger; Xiangguo Qiu
Journal:  Viral Immunol       Date:  2015-02       Impact factor: 2.257

6.  In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding.

Authors:  Rekha G Panchal; Gordon Ruthel; Tara A Kenny; George H Kallstrom; Douglas Lane; Shirin S Badie; Limin Li; Sina Bavari; M Javad Aman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

7.  Differential cholesterol binding by class II fusion proteins determines membrane fusion properties.

Authors:  M Umashankar; Claudia Sánchez-San Martín; Maofu Liao; Brigid Reilly; Alice Guo; Gwen Taylor; Margaret Kielian
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

8.  FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Authors:  Lisa M Johansen; Jennifer M Brannan; Sue E Delos; Charles J Shoemaker; Andrea Stossel; Calli Lear; Benjamin G Hoffstrom; Lisa Evans Dewald; Kathryn L Schornberg; Corinne Scully; Joseph Lehár; Lisa E Hensley; Judith M White; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-06-19       Impact factor: 17.956

9.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  25 in total

Review 1.  Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.

Authors:  David S Fedson
Journal:  Ann Transl Med       Date:  2016-11

2.  Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol.

Authors:  Monica I Alvarez; Luke C Glover; Peter Luo; Liuyang Wang; Elizabeth Theusch; Stefan H Oehlers; Eric M Walton; Trinh Thi Bich Tram; Yu-Lin Kuang; Jerome I Rotter; Colleen M McClean; Nguyen Tran Chinh; Marisa W Medina; David M Tobin; Sarah J Dunstan; Dennis C Ko
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-21       Impact factor: 11.205

3.  Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children.

Authors:  James J Gilchrist; Alexander J Mentzer; Anna Rautanen; Matti Pirinen; Salim Mwarumba; Patricia Njuguna; Neema Mturi; Thomas N Williams; J Anthony G Scott; Adrian V S Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-27       Impact factor: 11.205

4.  Hemodynamic shear stress induces protective autophagy in HeLa cells through lipid raft-mediated mechanotransduction.

Authors:  Joyjyoti Das; Somnath Maji; Tarun Agarwal; Suman Chakraborty; Tapas K Maiti
Journal:  Clin Exp Metastasis       Date:  2018-03-13       Impact factor: 5.150

5.  A GXXXA Motif in the Transmembrane Domain of the Ebola Virus Glycoprotein Is Required for Tetherin Antagonism.

Authors:  Mariana González-Hernández; Markus Hoffmann; Constantin Brinkmann; Julia Nehls; Michael Winkler; Michael Schindler; Stefan Pöhlmann
Journal:  J Virol       Date:  2018-06-13       Impact factor: 5.103

Review 6.  Filovirus Strategies to Escape Antiviral Responses.

Authors:  Judith Olejnik; Adam J Hume; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler; Elke Mühlberger
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

7.  Protein disulfide isomerases (PDIs) negatively regulate ebolavirus structural glycoprotein expression in the endoplasmic reticulum (ER) via the autophagy-lysosomal pathway.

Authors:  Bin Wang; Jing Zhang; Xin Liu; Qingqing Chai; Xiaoran Lu; Xiaoyu Yao; Zhichang Yang; Liangliang Sun; Silas F Johnson; Richard C Schwartz; Yong-Hui Zheng
Journal:  Autophagy       Date:  2022-02-07       Impact factor: 13.391

8.  Ebola virus glycoprotein interacts with cholesterol to enhance membrane fusion and cell entry.

Authors:  Jinwoo Lee; Alex J B Kreutzberger; Laura Odongo; Elizabeth A Nelson; David A Nyenhuis; Volker Kiessling; Binyong Liang; David S Cafiso; Judith M White; Lukas K Tamm
Journal:  Nat Struct Mol Biol       Date:  2021-01-18       Impact factor: 15.369

9.  Toremifene interacts with and destabilizes the Ebola virus glycoprotein.

Authors:  Yuguang Zhao; Jingshan Ren; Karl Harlos; Daniel M Jones; Antra Zeltina; Thomas A Bowden; Sergi Padilla-Parra; Elizabeth E Fry; David I Stuart
Journal:  Nature       Date:  2016-06-29       Impact factor: 49.962

10.  Structure of glycosylated NPC1 luminal domain C reveals insights into NPC2 and Ebola virus interactions.

Authors:  Yuguang Zhao; Jingshan Ren; Karl Harlos; David I Stuart
Journal:  FEBS Lett       Date:  2016-02-23       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.